Thinking of joining a study?

Register your interest

Become a volunteer?

NCT05868226 | RECRUITING | HER2-positive Breast Cancer

PRE-I-SPY Phase I/Ib Oncology Platform Program
Sponsor:

QuantumLeap Healthcare Collaborative

Brief Summary:

I-SPY Phase I/Ib (I-SPY-P1) is an open-label, multisite platform study designed to evaluate single agents or combinations in a metastatic treatment setting that may be relevant for breast cancer patients with the overall goal of moving promising drug regimens into the I-SPY 2 SMART Design Trial (NCT01042379) and/or other oncology-based trials in a timely manner.

Condition or disease

HER2-positive Breast Cancer

Metastatic Cancer

Metastatic Breast Cancer

Metastatic

HER2-positive Metastatic Breast Cancer

HER2 Mutation-Related Tumors

HER-2 Protein Overexpression

HER2-negative Breast Cancer

Triple Negative Breast Cancer

HR Positive

Hormone Receptor-positive Breast Cancer

Estrogen Receptor Positive Tumor

Progesterone Receptor-positive Breast Cancer

Hormone Receptor Negative Breast Carcinoma

Solid Tumor

Solid Tumor, Adult

Solid Carcinoma

HER2 Low Breast Cancer

HER2 Low Breast Carcinoma

Are positive breast cancer

PR-positive Breast Cancer

Intervention/treatment

ALX148

Fam-Trastuzumab Deruxtecan-Nxki

Zanidatamab

Tucatinib

Phase

PHASE1

Detailed Description:

The PRE-I-SPY/I-SPY-P1 study is a platform trial with multiple ongoing drug regimen arms. In most cases, the treatment arm will have a dose-finding group (Part 1) and a dose-expansion group (Part 2). Eligibility criteria will vary according to the experimental regimen. Participant eligibility may vary according to the arm or the part within the study arm, including with respect to diagnosis. Arms could include participants diagnosed with certain solid tumors or specifically with breast cancer. Arms may restrict enrollment to a certain molecular pathway abnormality or histologic diagnosis. The trial allows for various study arm designs, with the goal to complete analysis of a study arm in 12 to 18 months.

Study Type : INTERVENTIONAL
Estimated Enrollment : 124 participants
Masking : NONE
Primary Purpose : TREATMENT
Official Title : PRE-Investigation of Serial Studies to Predict Your Therapeutic Response With Imaging And moLecular Analysis: A Phase I/Ib Platform Trial
Actual Study Start Date : 2023-02-15
Estimated Primary Completion Date : 2028-12-30
Estimated Study Completion Date : 2029-12-30

Information not available for Arms and Intervention/treatment

Ages Eligible for Study: 18 Years
Sexes Eligible for Study: ALL
Accepts Healthy Volunteers:
Criteria
General Inclusion Criteria (GIC)
  • * GIC1: The participant must have ability to understand and willingness to provide signed written informed consent prior to any study related assessments and procedures and for collection of archival FFPE blocks (freshly cut 14 unstained tumor slides would be acceptable).
  • * GIC2: Age ≥ 18 years at the time of signing the informed consent
  • * GIC3: Gender: Male or female (premenopausal and postmenopausal)
  • * GIC4: ECOG performance status Grade 0-2
  • * GIC5: Estimated life expectancy \> 12 weeks at the start of investigational medicinal product (IMP) treatment.
  • * GIC6: Adequate organ function, evidenced by the following laboratory results within 30 days of the start of IMP
    • * Absolute neutrophil count ≥ 1,500/mm3
    • * Platelet count ≥ 100,000/mm3
    • * Hemoglobin ≥ 9.0 g/dL with no blood transfusion in the past 28 days
    • * Total bilirubin ≤ 1.5 x the upper limit of normal (ULN)
    • * Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) ≤ 3.0 x ULN
    • * Estimated Creatinine clearance (using Cockcroft-Gault formula) ≥ 60 mL/min for small molecules and \>30 mL/min for monoclonal antibodies unless otherwise specified in the Arm Specific Eligibility.
    • These cut-off values may be modified with supporting data for specific drug regimens.
    • * GIC7: Non-Pregnant: Serum or urine pregnancy test must be negative within 14 days of IMP treatment start in women of childbearing potential. Pregnancy testing does not need to be pursued in patients who are judged as postmenopausal before enrollment, or who have undergone bilateral oophorectomy, total hysterectomy, or bilateral tubal ligation. If male, they must agree to refrain from donating sperm during treatment.
    • * GIC8: Contraception: Women of childbearing potential and men must be willing to use adequate contraception for the duration of protocol treatment. Additional information regarding contraception for the specific treatment arm will be added to the drug arm description. Adequate contraception is defined as one highly effective form (i.e., abstinence, (fe)male sterilization) OR two effective forms (e.g., non-hormonal IUD and condom / occlusive cap with spermicidal foam / gel / film / cream / suppository).
    • * GIC9: Prior therapy effects: Resolution of all acute toxic effects of prior therapy, including radiotherapy, to grade ≤1 and neuropathy to grade ≤2 (except toxicities not considered a safety risk for the patient) and recovery from surgical procedures.
    • * GIC10: Participant compliance: Patients who are willing and able to comply with scheduled visits, treatment plan, laboratory tests, and other study procedures.
    • * Additional arm specific inclusion criteria as needed by drug arm regimen
    • General Exclusion Criteria (GEC)
      • * GEC1: Wash out periods: No other anticancer therapy within the following periods
        • * chemotherapy or investigational agents, 3 weeks
        • * mitomycin C and nitrosoureas, 6 weeks
        • * radiotherapy, 3 weeks
        • * targeted therapy, 2 weeks
        • * MAbs, ADCs, and immunotherapy, 3 weeks
        • * endocrine therapy, no washout needed
        • * GEC2: Concurrent therapy with other Investigational Products.
        • * GEC3: Prior history of drug/regimen hypersensitivity: History of infusion-related reactions and/or hypersensitivity to IMP or excipients of the study drug/drugs which led to permanent discontinuation of the treatment.
        • * GEC4: Uncontrolled intercurrent illness including (active infection, diabetes, pulmonary embolism in the past 6 months, or psychiatric illness/social situations that would limit compliance with study requirements).
        • * GEC5: Cardiovascular disease: History (within 6 months prior to start IMP) of clinically significant cardiovascular disease such as unstable angina, congestive heart failure (CHF), myocardial infarction, uncontrolled hypertension, cardiac arrhythmia requiring medication, or baseline corrected QT by Fridericia's formula (QTcF) length \> 470 msec for men and women. The QTcF cut-off value may be modified with supporting data for specific drug regimens.
        • * GEC6: CNS tumoral spread: Active uncontrolled/symptomatic central nervous system cancer/spinal cord compression. Previously treated and clinically stable lesions, as per Investigator's judgment, are permitted. Newly discovered asymptomatic lesions that are not life threatening and do not require urgent local treatment to ensure patient safety, after consultation with study regimen chaperones, may be permitted.
        • * GEC7: Liver disease: Patients with clinically significant history of liver disease, including viral or other known hepatitis, current alcohol abuse, or cirrhosis.
        • * GEC8: Recent major surgery within 4 weeks prior to start IMP treatment
        • * GEC9: Pregnancy or breastfeeding
        • * GEC10: Individuals accommodated in an institution because of regulatory or legal order; prisoners or participants who are legally institutionalized.
        • * GEC11: Other conditions, which in the opinion of the investigator, would compromise the safety of the patient or the patient's ability to complete the study.
        • * GEC12: Concomitant malignancies: A diagnosis of a malignancy in the 2 years prior to starting study treatment other than the disease under study. Exceptions include indolent or definitively treated malignancy not expected to require treatment during the study, affect the safety of subjects, or affect the endpoints of the trial.
        • * Additional arm specific exclusion criteria as needed by drug arm regimen
PRE-I-SPY Phase I/Ib Oncology Platform Program

Location Details

NCT05868226

Please Choose a site

How to Participate

Want to participate in this study, select a site at your convenience, send yourself email to get contact details and prescreening steps.

Locations

RECRUITING

United States, Albama

The University of Alabama at Birmingham O'Neal Comprehensive Cancer Center

Birmingham, Albama, United States, 35233

RECRUITING

United States, Florida

Moffitt Cancer Center

Tampa, Florida, United States, 33612

RECRUITING

United States, Illinois

The University of Chicago Medicine Comprehensive Cancer Center

Chicago, Illinois, United States, 60637

RECRUITING

United States, Illinois

UChicago Medicine Comprehensive Cancer Center at Silver Cross Hospital

New Lenox, Illinois, United States, 60451

RECRUITING

United States, Illinois

UChicago Medicine Orland Park

Orland Park, Illinois, United States, 60462

RECRUITING

United States, Minnesota

University of Minnesota Masonic Cancer Center

Minneapolis, Minnesota, United States, 55455

RECRUITING

United States, Texas

The University of Texas MD Anderson Cancer Center

Houston, Texas, United States, 77030